AstraZeneca’s (AZN) “Buy” Rating Reiterated at Berenberg Bank

Berenberg Bank reaffirmed their buy rating on shares of AstraZeneca (LON:AZN) in a research report sent to investors on Wednesday morning, Marketbeat Ratings reports. Berenberg Bank currently has a GBX 140 ($1.81) price objective on the biopharmaceutical company’s stock.

A number of other brokerages also recently commented on AZN. JPMorgan Chase & Co. restated an “overweight” rating on shares of AstraZeneca in a research note on Wednesday, February 19th. Shore Capital restated a “buy” rating on shares of AstraZeneca in a report on Friday, March 7th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of GBX 7,542.80 ($97.63).

AstraZeneca Stock Up 1.9 %

Shares of AZN opened at £114.14 ($147.73) on Wednesday. The firm has a fifty day moving average price of £115.86 and a 200-day moving average price of £112.81. The company has a current ratio of 0.93, a quick ratio of 0.59 and a debt-to-equity ratio of 73.83. The firm has a market capitalization of £219.61 billion, a P/E ratio of 31.29, a P/E/G ratio of 0.86 and a beta of 0.17. AstraZeneca has a 12-month low of GBX 9,670 ($125.16) and a 12-month high of £133.88 ($173.29).

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.